Large clinical trials and meta-analyses have revealed that SGLT2 inhibitors can reduce the incidence of atrial and ventricular arrhythmias in patients with HF, regardless of whether they have diabetes. The gene discussed is SLC5A2; the disease is hydrops fetalis.